Transperineal biopsy is a biopsy procedure in which a sample of tissue is removed from the prostate for examination under a microscope. The sample is removed with a thin needle that is inserted through the skin of the perineum (between the scrotum and anus) and into the prostate. Imaging is obtained by an ultrasound probe passed into the rectum. This approach has the potential for improved sampling, particularly in men who have had a previous negative Transrectal (TRUS) biopsy.
The transperineal biopsy has the additional potential advantage of a much lower risk of infection, as the skin of the perineum can be easily disinfected by routine surgical preparation immediately prior to the procedure, whilst with TRUS biopsy there is a significant risk of infection from bacteria entering the bloodstream because the biopsy needle passes through the rectal wall. In addition, the transperineal path enables approaching also the ventral prostate areas, typically omitted in the usual transrectal TRUS methodology.
BiopSee® Solution: U/S-MRI image fusion & navigated TP biopsy
General success rate 58%-70%
Targeted on mp-MRI-suspicious locations 86%-100%
CLINICAL RESULTS: CANCER DETECTION WITH BiopSee®
MRI suspicious areas: 86-100%
MRI non-suspicious areas: 12%
- MRI does not detects all CA (false negatives)
CA detection probability per core
30% CA in MRI-targeted cores
8% CA in random systematic cores
- MRI indicates more CA (false positives)
- Navigated cores are not enough, additional systematic sampling needed
Target accuracy (stereotactically): 1.7 mm